Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program
On November 11, 2025, Jones Trading’s Soumit Roy reiterated his “Buy” rating on Janux Therapeutics, Inc.
Janux Therapeutics Inc. (JANX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 11,189,693 | $273,476,097 | 3.37% | |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 2,775,000 | $67,821,000 | +10% | 0.11% |
| 3. | OrbiMed Advisors Samuel Isaly | 1,766,100 | $43,163,484 | +46% | 1.01% |
| 4. | Point72 Asset Management Steve Cohen | 1,710,200 | $41,797,288 | -21% | 0.07% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,026,938 | $25,098,365 | -18% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.02 | 110,206 | $3,418,590.12 | 10,141,287 | 2025-03-07 | Filing | |
| $30.78 | 372,093 | $11,453,022.54 | 10,031,081 | 2025-03-06 | Filing | |
| $31.30 | 37,455 | $1,172,341.50 | 9,658,988 | 2025-03-05 | Filing | |
| $30.56 | 304,287 | $9,299,010.72 | 9,621,533 | 2025-03-05 | Filing | |
| $44.75 | 1,200,000 | $53,700,000.00 | 9,317,246 | 2024-10-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.00 | 3,333 | $99,990.00 | 84,974 | 2025-11-14 | Filing | |
| $30.06 | 16,665 | $500,986.56 | 82,139 | 2025-10-28 | Filing | |
| $32.60 | 400 | $13,041.36 | 82,139 | 2025-05-01 | Filing | |
| $31.95 | 2,933 | $93,703.19 | 82,539 | 2025-05-01 | Filing | |
| $30.00 | 3,334 | $100,020.00 | 82,139 | 2025-04-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,056,062 | $221,330,155 | 0.01% | |
| 2. | 4,701,112 | $114,988,241 | 0.05% | |
| 3. | 3,730,994 | $91,185,492 | 0% | |
| 4. | 2,920,258 | $71,371,106 | 2.03% | |
| 5. | 2,417,104 | $59,074,022 | 0% |
News See All
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best small cap stocks with the highest upside. Janux Therapeutics, Inc.
11 Best Small Cap Stocks with the Highest Upside
She stated that small caps show possibility, as a lot of them are rate sensitive, a little bit more levered, and are helped by lower rates, which is why there has been a lot of momentum behind small caps...
Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT
Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential.
10 Best Up and Coming Stocks with Huge Upside Potential
On August 20, Andres Garcia-Amaya, Zoe Financial CEO, joined 'The Exchange' on CNBC to discuss how IPO pops will draw in private companies to become public.
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration
Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential.
9 Best Small Cap Stocks with Biggest Upside Potential
On August 14, Jonathan Krinsky of BTIG, joined 'Closing Bell' on CNBC to discuss whether the recent rally in small cap stocks is sustainable.
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading analyst Soumit Roy maintained a bullish stance on Janux Therapeutics, Inc.
13 Small Cap Stocks Analysts Are Bullish On
On June 23, Jason Thomas, Carlyle's head of global research and investment strategy, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the market and economy in light of the recent financial...